Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors

Summary

The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate polypeptide sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the polypeptide vaccine for immunotherapy of human cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the polypeptide vaccine immunotherapy on human cancers will firstly be evaluated.

Timeline

Start

2024-06-04

Primary completion

2029-12-30

Completion

2037-12-30

Drugs

Indications